Bergeron R J, Wiegand J, McManis J S, McCosar B H, Weimar W R, Brittenham G M, Smith R E
Department of Medicinal Chemistry, University of Florida, Gainesville, Florida 32610-0485, USA.
J Med Chem. 1999 Jul 1;42(13):2432-40. doi: 10.1021/jm990058s.
Additional structure-activity studies of desferrithiocin analogues are carried out. The effects of stereochemistry at C-4 on the ligands' iron clearing efficiency are reviewed and assessed using the enantiomers 4,5-dihydro-2-(2, 4-dihydroxyphenyl)thiazole-4(R)-carboxylic acid and 4,5-dihydro-2-(2, 4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid. The utility of 4'-hydroxylation as a method of reducing the toxicity of desazadesferrithiocin analogues is also examined further with the synthesis and in vivo comparison of 4, 5-dihydro-2-(2-hydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid, which is the natural product 4-methylaeruginoic acid, and 4, 5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid. The stereochemistry at C-4 is shown to have a substantial effect on the iron clearing efficiency of desferrithiocin analogues, as does C-4'-hydroxylation on the toxicity profile. All of the compounds are evaluated in a bile-duct-cannulated rodent model to determine iron clearance efficiency and are carried forward to the iron-overloaded primate for iron clearing measurements. On the basis of the results of the present work, although 4,5-dihydro-2-(2, 4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid is still the most promising candidate for clinical evaluation, 4,5-dihydro-2-(2, 4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid (4'-hydroxydesazadesferrithiocin) also merits further preclinical assessment.
开展了去铁硫菌素类似物的额外构效关系研究。使用对映体4,5-二氢-2-(2,4-二羟基苯基)噻唑-4(R)-羧酸和4,5-二氢-2-(2,4-二羟基苯基)噻唑-4(S)-羧酸,综述并评估了C-4位立体化学对配体铁清除效率的影响。还通过合成天然产物4-甲基铜绿菌素4,5-二氢-2-(2-羟基苯基)-4-甲基噻唑-4(S)-羧酸以及4,5-二氢-2-(2,4-二羟基苯基)-4-甲基噻唑-4(S)-羧酸并进行体内比较,进一步研究了4'-羟基化作为降低去氮去铁硫菌素类似物毒性方法的效用。结果表明,C-4位立体化学对去铁硫菌素类似物的铁清除效率有显著影响;同样,C-4'位羟基化对毒性特征也有显著影响。所有化合物均在胆管插管的啮齿动物模型中进行评估以确定铁清除效率,并进一步用于铁过载灵长类动物的铁清除测量。基于本研究结果,尽管4,5-二氢-2-(2,4-二羟基苯基)噻唑-4(S)-羧酸仍是临床评估最有前景的候选物,但4,5-二氢-2-(2,4-二羟基苯基)-4-甲基噻唑-4(S)-羧酸(4'-羟基去氮去铁硫菌素)也值得进一步进行临床前评估。